EMG
KALA icon

Ellington Management Group’s KALA BIO KALA Stock Holding History

Ellington Management Group’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7
Closed -$160K – 237
2020
Q1 		$160K Buy
+7
New +$112K 0.04% 463

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ellington Management Group's KALA Position: Q2 2020 in Review

Ellington Management Group sold out of KALA BIO (KALA) in Q2 2020, closing a stake of 7 shares — an estimated $160K sold.

Ellington Management Group first reported a position in KALA in Q1 2020 and held it in 1 quarter. The position peaked at $160K in Q1 2020. 113 funds tracked by Wall St. Rank hold KALA as of Q2 2020.

  • Ellington Management Group reported no remaining KALA BIO position as of Q2 2020 after selling out during the quarter.
  • Ellington Management Group sold 7 KALA BIO shares in Q2 2020, an estimated $160K.
  • Ellington Management Group first reported a position in KALA BIO in Q1 2020 and held it in 1 quarter.
  • Ellington Management Group's KALA BIO position peaked at $160K in Q1 2020.
  • 113 funds tracked by Wall St. Rank held KALA BIO as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.